Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

导出 OA

翻译打印收藏纠错

作者： Timothy A,Yap ^[1] ; Li,Yan ^[2] ; Amita,Patnaik ^[3] ; Nina,Tunariu ^[4] ; Andrea,Biondo ^[1] ; Ivy,Fearen ^[2] ; Kyriakos P,Papadopoulos ^[3] ; David,Olmos ^[1] ; Richard,Baird ^[1] ; Liliana,Delgado ^[2] ; Ernestina,Tetteh ^[2] ; Robert A,Beckman ^[2] ; Lisa,Lupinacci ^[2] ; Ruth,Riisnaes ^[5] ; Shaun,Decordova ^[5] ; Simon P,Heaton ^[5] ; Karen,Swales ^[5] ; Nandita M,deSouza ^[4] ; Martin O,Leach ^[4] ; Michelle D,Garrett ^[5] ; Daniel M,Sullivan ^[6] ; Johann S,de Bono ^[7] ; Anthony W,Tolcher ^[3]

作者单位： Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom. ^[1] Merck & Co., Inc., Whitehouse Station, New Jersey. ^[2] South Texas Accelerated Research Therapeutics, San Antonio, Texas. ^[3] CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. ^[4] Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom. ^[5] H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[6] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom. johann.de-bono@icr.ac.uk. ^[7]